The first three for distinct types of cancer: midostaurin (RydaptTM) for FLT3-positive acute myeloid leukemia; neratinib (NerlynxTM) for HER2-positive breast cancer; and acalabrutinib (CalquenceTM) for Mantle cell lymphoma and, finally, latanoprostene (VyzultaTM) for glaucoma-ocular hypertension. This evidence concerns the gene ERBB2 and breast carcinoma.